FIRST AMENDMENT TO MANUFACTURING SERVICES AGREEMENT
Exhibit 10.56
CONFIDENTIALEXECUTION VERSION
Certain identified information has been excluded from this exhibit because such information both (i) is not material and (ii) would likely cause competitive harm if publicly disclosed. Excluded information is indicated with brackets and asterisks [*****].
FIRST AMENDMENT TO MANUFACTURING SERVICES AGREEMENT
THIS FIRST AMENDMENT to the MANUFACTURING SERVICES AGREEMENT (“First Amendment”) is made and entered into on this 6th day of March 2023 (“First Amendment Effective Date”), by and between ACORDA THERAPEUTICS, INC. (“Acorda”), a Delaware corporation, and CATALENT MASSACHUSETTS, LLC (“Manufacturer”), a Delaware limited liability company.
RECITALS
WHEREAS, Acorda and Manufacturer entered into a Manufacturing Services Agreement having an effective date of 1 January 2023 (“Agreement”) pursuant to which Manufacturer provides manufacturing and related services to Acorda; and
WHEREAS, the Parties desire to amend the Agreement as set forth herein.
NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, have agreed to amend the terms of the Agreement as follows:
(c) Milestone Payment. In consideration of activities required to complete the installation of the PSD-7 equipment for operational readiness, Acorda shall pay Manufacturer a milestone payment in the total amount of two million dollars ($2,000,000), payable as set forth below. (For clarity, operational readiness is defined as equipment modifications and upgrades required to support the manufacturing of Inbrija (“Operational Readiness”)).
ii [*****] to be invoiced as of [*****], 2023
Page 1 of NUMPAGES 2
Exhibit 10.56
CONFIDENTIALEXECUTION VERSION
b. Schedule 4, Pricing and Reserved Capacity, of the Agreement shall be modified as follows. The Tier 2 Market Pricing for year 2023 for product produced on the PSD-4 shall be increased from $[*****] per Batch to $[*****] per Batch.
IN WITNESS WHEREOF, the Parties have executed this First Amendment as of the First Amendment Effective Date above written.
CATALENT MASSACHUSETTS, LLC |
ACORDA THERAPEUTICS, INC. |
Signature: ___________________________ |
Signature: _________________________ |
Name: Xxxxx Xxxxxx |
Name: Xxx Xxxxx |
Title: President, Clinical Development and Supply, Catalent Pharma Solutions
|
Title: President & Chief Executive Officer |
Date: |
Date: |
Page 2 of NUMPAGES 2